… the development of the disease in rat models[198]. Furthermore, … or in combination with
Sorafenib or Erlotinib in patients with … orthotopic human HCC xenografts results in reduced tumor …

… strategy for hepatocellular carcinoma (HCC) treatment. … that a combination of sorafenib plus
erlotinib did not result in … engineered mouse models with orthotopic liver cancer. The results …

… We further observed the effects of NZ001 and sorafenib … -6 orthotopic mice model, we
found that inhibition of VEGF signaling by multitargeted RTK inhibitor sorafenib slowed tumor …

… Doxorubicin (Dox) and sorafenib (Sor) were used as model drugs whose PK data were …
of tumor growth or biomarkers in animal models as well as patients with cancer subjected to …

… Due to the dearth of medical therapy for HCC, sorafenib was … growth factor receptor inhibitors
erlotinib and lapatinib, MEK1/… factor of outcome after orthotopic liver transplantation.100 A …

… cancer cells. Overall, this study provides a new combined strategy for the clinical treatment
of hepatocellular carcinoma. … , erlotinib) and VEGF/VEGFR inhibitors in cancer treatment may …

… linked to improved preclinical and animal models and has to be … than single agents like the
sorafenib/erlotinib combination[33]. … , these models can be combined with GEM or orthotopic …

… –small-cell lung cancer (27), and Tarceva for EGFR-mutated … sorafenib induced slight
retardation of tumor growth in the HuH-7 orthotopic xenograft and Hep3B2.1-7 xenograft models…

… In mice, the recapitulation of human breast tumor orthotopic … Erlotinib EGFR Phase 3 failure
in combination with sorafenib … In this context, the development of animal models mimicking …

… trial of sorafenib plus erlotinib versus sorafenib plus placebo … effect of sorafenib in both
orthotopic and ectopic models of … hepatocellular carcinoma. Proceedings of the 14th European …